Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008
dc.conference.date | SEP 16-21, 2021 | |
dc.conference.title | Congress of the European-Society-for-Medical-Oncology (ESMO) | |
dc.contributor.author | Eigentler, T. | |
dc.contributor.author | Heinzerling, L. | |
dc.contributor.author | Krauss, J. | |
dc.contributor.author | Weishaupt, C. | |
dc.contributor.author | Ochsenreither, S. | |
dc.contributor.author | Lebbe, C. | |
dc.contributor.author | Mohr, P. | |
dc.contributor.author | Oliva, M. | |
dc.contributor.author | Oberoi, H. K. | |
dc.contributor.author | Terheyden, P. | |
dc.contributor.author | Perez, J. M. Trigo | |
dc.contributor.author | Robert, C. | |
dc.contributor.author | Bauernfeind, F-G. | |
dc.contributor.author | Fluck, M. | |
dc.contributor.author | Richtig, E. | |
dc.contributor.author | Soria, A. | |
dc.contributor.author | Kays, S-K. | |
dc.contributor.author | Schmitt-Bormann, B. | |
dc.contributor.author | Falk, M. | |
dc.contributor.author | Gnad-Vogt, U. S. | |
dc.contributor.authoraffiliation | [Eigentler, T.] Univ Tubingen, Dept Dermatol, Tubingen, Germany | |
dc.contributor.authoraffiliation | [Heinzerling, L.] Univ Klin Erlangen, Dept Dermatol, Erlangen, Germany | |
dc.contributor.authoraffiliation | [Krauss, J.] Univ Klinikum Heidelberg, Zentrum Innere Med, Krehl Klin, Dept Med Oncol, Heidelberg, Germany | |
dc.contributor.authoraffiliation | [Weishaupt, C.] UKM Univ Hosp Muenster, Dermatol, Munster, Germany | |
dc.contributor.authoraffiliation | [Ochsenreither, S.] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany | |
dc.contributor.authoraffiliation | [Lebbe, C.] Hop St Louis, AP HP, Policlin Dermatol, Paris, France | |
dc.contributor.authoraffiliation | [Mohr, P.] Elbe Klinikum Buxtehude, Dermatol, Buxtehude, Germany | |
dc.contributor.authoraffiliation | [Oliva, M.] Catalan Inst Oncol ICO LHospitalet, Phase Drug Dev Program 1, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Oberoi, H. K.] Vall dHebron Inst Oncol VHIO, Cellex Ctr, Med Oncol Dept, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Terheyden, P.] Univ SH Lubeck, Dermatol, Lubeck, Germany | |
dc.contributor.authoraffiliation | [Perez, J. M. Trigo] Hosp Univ Virgen Victoria, Med Oncol Dept, Malaga, Spain | |
dc.contributor.authoraffiliation | [Robert, C.] Inst Gustave Roussy, Dermatol Dept, Villejuif, France | |
dc.contributor.authoraffiliation | [Bauernfeind, F-G.] Univ Klinikum Bonn, Dept Internal Med Oncol Hematol & Rheumatol 3, Bonn, Germany | |
dc.contributor.authoraffiliation | [Fluck, M.] Fachklin Hornheide, Internist Onkol, Munster, Germany | |
dc.contributor.authoraffiliation | [Richtig, E.] Univ Klin Dermatol & Venerol, Dermatol, Graz, Austria | |
dc.contributor.authoraffiliation | [Soria, A.] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain | |
dc.contributor.authoraffiliation | [Kays, S-K.] CureVac AG, Translat & Clin Sci, Frankfurt, Germany | |
dc.contributor.authoraffiliation | [Schmitt-Bormann, B.] CureVac AG, Clin Dev, Frankfurt, Germany | |
dc.contributor.authoraffiliation | [Falk, M.] CureVac AG, Clin Dev, Frankfurt, Germany | |
dc.contributor.authoraffiliation | [Gnad-Vogt, U. S.] CureVac AG, Clin Dev, Frankfurt, Germany | |
dc.contributor.funder | CureVac AG | |
dc.date.accessioned | 2025-01-07T15:21:04Z | |
dc.date.available | 2025-01-07T15:21:04Z | |
dc.date.issued | 2021-09-21 | |
dc.identifier.doi | 10.1016/j.annonc.2021.08.1394 | |
dc.identifier.essn | 1569-8041 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.unpaywallURL | https://doi.org/10.1016/j.annonc.2021.08.1394 | |
dc.identifier.uri | https://hdl.handle.net/10668/27062 | |
dc.identifier.wosID | 700527702028 | |
dc.issue.number | 5 | |
dc.journal.title | Annals of oncology | |
dc.journal.titleabbreviation | Ann. oncol. | |
dc.language.iso | en | |
dc.organization | SAS - Hospital Universitario Virgen de la Victoria | |
dc.organization | SAS - Hospital Universitario Virgen de la Victoria | |
dc.page.number | S853-S853 | |
dc.publisher | Elsevier | |
dc.rights.accessRights | open access | |
dc.title | Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008 | |
dc.type | conference output | |
dc.type.hasVersion | VoR | |
dc.volume.number | 32 | |
dc.wostype | Meeting Abstract |